Patients have started asking for a weight loss drug by name that is not on any pharmacy shelf yet. We asked Dr. Frank Agullo to sort out what is real about retatrutide and what people should do with the answer.
Start With What It Is
Dr. Agullo: “Retatrutide is a triple hormone receptor agonist that targets three pathways: GLP-1, GIP and glucagon receptors.”
“At this time, there is no FDA-approved branded retatrutide product available.”
How This Class Works at All
Before the new molecule, the older ones. This is how Dr. Agullo explains the category to patients in the room:
“The GLP-1 originally came out as a medication for diabetics. There are receptors in the stomach that make us feel full, and that same signaling helps lower blood sugar, which is how it helps diabetics control their sugar. It also communicates with the brain so your appetite goes down, you feel fuller and more satisfied, and it slows the intestine so your portions naturally get smaller. You eat the same way but smaller portions, and certain foods, like very greasy or very sugary foods, stop appealing to you. So your blood sugar comes down, your insulin comes down, your cortisol comes down, and the insulin resistance starts to rebalance.”
“Semaglutide was the first one and has just one component, GLP-1. Tirzepatide has two components, GLP-1 and GIP. It helps more with inflammation, helps with more weight loss, and has fewer side effects like nausea, heartburn, and vomiting.”
One receptor, then two. Retatrutide adds a third, glucagon, which is tied to how the body spends energy rather than only to appetite and insulin.
What the Trial Actually Showed
Lilly published Phase 3 TRIUMPH-1 results in May 2026. The trial randomized 2,339 adults with obesity or overweight to one of three doses or placebo, and measured at 80 weeks.
| Dose | Average weight loss at 80 weeks |
|---|---|
| 4 mg | 19.0 percent, about 47 pounds |
| 9 mg | 25.9 percent, about 64 pounds |
| 12 mg | 28.3 percent, about 70 pounds |
| Placebo | 2.2 percent, about 6 pounds |
At 12 mg, 45.3 percent of participants lost at least 30 percent of their body weight and 65.3 percent finished under a BMI of 30. A smaller extension group with a starting BMI of 35 or higher reached 30.3 percent, about 85 pounds, at 104 weeks.
Everyone started at 2 mg once weekly and stepped up every four weeks. Dr. Agullo escalates the approved medications the same way:
“We start with the smallest dose, which is 2.5 milligrams, for four weeks, and I see how you feel. If you are doing well I increase the dose depending on how you feel. If you are losing a good amount of weight, I keep you at that dose until you stop losing, then we go up again.”
The Part the Headlines Skip
At 12 mg, 42.4 percent reported nausea, 32.0 percent diarrhea, 26.1 percent constipation and 25.3 percent vomiting. Abnormal skin sensation showed up in 12.5 percent at that dose against 0.9 percent on placebo, and 11.3 percent stopped treatment over side effects against 4.9 percent on placebo.
The 4 mg dose produced 19 percent weight loss with one escalation step and fewer dropouts than placebo. The biggest number on the chart is not automatically the right prescription.
Is It Better Than What We Have?
Dr. Agullo: “Retatrutide, being a triple agonist targeting GLP-1, GIP, and glucagon receptors, may offer greater weight loss potential than semaglutide and tirzepatide. Semaglutide is a GLP-1 receptor agonist, whereas tirzepatide is a dual GLP-1 and GIP receptor agonist.
“Patient selection should be individualized rather than based on one peptide. Patients with obesity or overweight accompanied by metabolic complications such as prediabetes, insulin resistance, metabolic dysfunction-associated fatty liver, or cardiometabolic risk factors may all be appropriate candidates for any of the GLP forms.
“Selection should take into account the patient’s medical history, contraindications, treatment goals, metabolic profile, tolerability, and the specific medication indications.”
May. Retatrutide has not been compared head to head against tirzepatide in a completed trial.
Where Approval Stands
Lilly had signaled a possible FDA submission before the end of 2026. In July the company moved that to the first quarter of 2027, citing the manufacturing and quality control data still to be assembled. Submission is not approval, and review runs months beyond it.
On Buying It Somewhere Else
Dr. Agullo: “An important safety consideration with GLP-1 based therapies and other peptide treatments is the importance of ongoing evaluation, treatment, and follow-up by a qualified licensed medical professional. Patients should undergo appropriate screening before treatment.
“Appropriate clinical oversight and sourcing medication through legitimate, appropriately licensed pharmacies can also help reduce the risk of obtaining counterfeit, contaminated, improperly compounded or otherwise unsafe products from unverified sources.
“Patients should be educated to obtain their medications only through authorized and reputable channels and to avoid products purchased from unverified websites, social media, or any other unauthorized sellers.”
What Is Available Right Now
Approved medications work, and the medically supervised weight loss program runs on screening, labs, and follow up rather than on whichever molecule is trending. Dr. Agullo’s instructions to patients on treatment do not change with the drug:
“Your appetite will go down. Many patients stop eating and only eat at mealtime, but I do not want you to do that, because if your blood sugar drops you will feel tired. I want you to eat small amounts during the day, snacking on something like a fruit, so your blood sugar stays more stable. I also want you to eat more protein so you do not lose as much muscle and we burn more fat.”
“Walk twenty to thirty minutes a day. Once you feel a little better, add light weights while you walk. That helps the muscle grow and burns more fat.”
For patients whose weight loss has already outpaced their skin, body contouring is a separate conversation worth having at the right moment. Our Med Spa and peptide wellness program cover the non-surgical side.
Dr. Agullo writes about the same subject from his own chair at agulloplasticsurgery.com and drworldwide.com.
Dr. Agullo is certified by the American Board of Plastic Surgery and the American Board of Surgery, completed his plastic surgery fellowship at the Mayo Clinic, and serves as Clinical Associate Professor of Plastic Surgery at Texas Tech University Health Sciences Center. He has been a Castle Connolly Top Doctor for thirteen consecutive years.
Ready to Talk?
If you came here looking for retatrutide, come in and talk about what is actually available. And if you have already bought something online, bring the vial with you. An honest evaluation beats guessing.
Call (915) 590-7900, text 1-866-814-0038, or book online at agulloplasticsurgery.com. #StayBeautiful
@RealDrWorldWide on Instagram, TikTok, and Snapchat, @Agullo on X, or @AgulloPlasticSurgery on Facebook.
